What this means
This trial plans to check whether treating a leaky tricuspid heart valve helps kidney function and physical activity. It has not reported results, so it cannot yet show whether those changes happen.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.
- Trial ID
- NCT07464106 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Cardio-Renal Syndrome, Frailty
- What is tested
- Transcatheter edge-to-edge repair (TEER)
- Sponsor
- Robert Bosch Medical Center
- Ages
- 18 Years to no maximum
- Dates
- First posted Mar 11, 2026 · updated Mar 11, 2026
Registry summary
The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.
Sites (1)
- Robert Bosch Hospital, Stuttgart, Germany